Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Original Articles

Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ⩾10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients

Bone Marrow Transplantation volume 37, pages 51–56 (2006)Cite this article

Abstract

Quantitative polymerase chain reaction (QPCR) for cytomegalovirus (CMV) is emerging as the preferred screening method for detection of CMV viremia in patients following allogeneic bone marrow and peripheral blood stem cell transplant. However, there are currently no universally accepted QPCR treatment thresholds at which to start pre-emptive therapy. We report here results of a pre-emptive therapy strategy using ganciclovir (GCV) 5 mg/kg initiated once daily (ODG) delayed till a threshold CMV load of ⩾10 000 copies/ml whole blood in clinically stable patients. Sixty-nine at risk patients underwent allogeneic stem cell transplant. 48/69 (70%) patients had an initial episode of CMV viremia. 5/48 (10%) cleared viremia without requiring treatment. 28/43 (65%) patients requiring treatment initiated treatment with ODG. 17/28 (61%) patients successfully cleared CMV viremia on ODG, 10/28 (36%) patients required dose escalation to twice daily GCV for increasing viral loads. There were two cases of CMV disease (colitis) and no deaths due to CMV disease in patients initiating treatment with ODG. We conclude delaying pre-emptive therapy with ODG until whole blood QPCR⩾10 000 copies/ml is a safe and effective strategy for CMV viremia after allogeneic stem cell transplant in clinically stable patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Winston DJ, Ho WG, Lin CH, Bartoni K, Budlinger MD, Gale RP et al. Intraveneous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12–18.

    Article  CAS  PubMed  Google Scholar 

  2. Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488.

    Article  CAS  PubMed  Google Scholar 

  3. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR . A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997; 24: 901–907.

    Article  CAS  PubMed  Google Scholar 

  4. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  5. Goodrich JM, Mori M, Gleaves CA, DuMond C, Cays M, Ebling DF et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–1607.

    Article  CAS  PubMed  Google Scholar 

  6. Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Ohnishi M et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437–444.

    Article  CAS  PubMed  Google Scholar 

  7. Gleaves CA, Smith TF, Shuster EA, Pearson GR . Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917–919.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD . Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358–1364.

    CAS  PubMed  Google Scholar 

  9. Qamruddin AO, Oppenheim BA, Guiver M, Mutton KJ, Chopra R . Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301–306.

    Article  CAS  PubMed  Google Scholar 

  10. Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777–782.

    Article  CAS  PubMed  Google Scholar 

  11. Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001; 28: 765–768.

    Article  CAS  PubMed  Google Scholar 

  12. Einsele H, Ehninger G, Hebart H, Wittowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.

    CAS  PubMed  Google Scholar 

  13. Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH . Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol 2001; 39: 4362–4369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hassan-Walker AF, Kidd IM, Sabin C, Sweny P, Griffiths PD, Emery VC . Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182–187.

    Article  CAS  PubMed  Google Scholar 

  15. Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant 2003; 32: 703–707.

    Article  CAS  PubMed  Google Scholar 

  16. Sanchez JE, Storch GA . Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA. J Clin Microbiol 2002; 40: 2381–2386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant 2002; 29: 599–606.

    Article  CAS  PubMed  Google Scholar 

  18. Haddad N, Galbraith J, Vij R, DiPersio JF, Shannon J, Duncan W et al. PCR versus culture for diagnosis and management of CMV in allogeneic stem cell transplant (SCT) recipients. Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America 2002, p 142 (Abstract 304).

  19. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597–605.

    Article  CAS  PubMed  Google Scholar 

  20. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032–2036.

    Article  CAS  PubMed  Google Scholar 

  21. Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782–790.

    CAS  PubMed  Google Scholar 

  22. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  23. Trenschel R, Ross S, Husing J, Ottinger H, Elmaagacli A, Roggendorf M et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665–672.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA

    L A Verkruyse, S M Devine, J F DiPersio & R Vij

  2. Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA

    G A Storch

Authors
  1. L A Verkruyse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G A Storch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S M Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J F DiPersio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Vij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Vij.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verkruyse, L., Storch, G., Devine, S. et al. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ⩾10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 37, 51–56 (2006). https://doi.org/10.1038/sj.bmt.1705213

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705213

Keywords

This article is cited by

Search

Advanced search

Quick links